HIV Vaccine Clinical Research Trials

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

The purpose of this study is to evaluate the steady state pharmacokinetics (PK) of rilpivirine (RPV) and determine the appropriate dose of RPV in combination with other antiretrovirals (ARVs) in participants aged greater than or equal to 2 to less than 12 years and to evaluate the safety and tolerability …

HIV Vaccine

abacavir

dolutegravir

antiretroviral agents

immunodeficiency

53 views
02 Dec, 2020
19 locations

Translating the ABCS Into HIV Care

The overall objective of this project is to develop and rigorously test implementation strategies to address the gap in scientific knowledge of lower use of evidence-based interventions commonly referred to as the ABCS (aspirin, blood pressure control, cholesterol control, and smoking cessation)which contributes to the growing CVD morbidity and mortality …

0 views
01 Dec, 2020
1 location

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

The goal of this project is to rigorously evaluate the efficacy of HIV Infant Tracking System 2.1 (HITSystem, an eHealth intervention that uses short message service (SMS) texts to patients and algorithm-driven electronic alerts for providers) to increase retention in guideline-adherent prevention of mother-to-child transmission of HIV services (PMTCT) and …

0 views
12 Nov, 2020
3 locations

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

of HIV infection because they can protect macaques from infection, and the presence of anti-HIV antibodies was the only positive correlate of protection in an HIV vaccine efficacy trial (RV144 trial

0 views
16 Mar, 2020
1 location

TB Screening Improves Preventive Therapy Uptake

HIV-infected people have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among people living with HIV (PLHIV), the World Health Organization (WHO) recommends systematic TB screening followed by 1) confirmatory TB testing for all those who screen positive and 2) TB preventive therapy (TPT) …

0 views
24 Dec, 2020
1 location

Leveraging the HIV Platform for Hypertension Control in Uganda (INTEGRATED HIV/HTN) STUDY

The INTEGRATED HIV/HTN is a hybrid type-1 effectiveness/implementation cluster randomised trial evaluating the introduction of a multi-component integrated HIV/HTN care model intervention, randomised to 13 districts in the intervention arm compared to 13 districts in the control. Selected health facilities within the 13 intervention districts will receive the intervention while …

0 views
07 Dec, 2020
1 location

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine

ACTHIVE-001 is a randomised, open-label, uncontrolled phase 1 clinical trial to determine the safety profile of the native-like HIV-1 envelope vaccine, ConM SOSIP.v7, adjuvanted with monophosphoryl lipid A (MPLA) liposomes. The study will furthermore determine the extent to which the vaccine influences the breadth of viruses neutralised by induced antibodies …

4 views
17 Jan, 2021
1 location

EPIC-P Intervention

This non-randomized, open-label study will address the following research aims in People who inject drugs (PWID): To assess the feasibility and acceptability of the Expanding PrEP Implementation in Communities of PWID (EPIC-P) intervention among high-risk PWID. To determine the preliminary efficacy of the EPIC-P intervention in terms of increasing adherence …

AIDS prevention

AIDS

drug use

injection drug

0 views
14 Jan, 2021
1 location

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

This research study is being carried out to study a new way to possibly treat HIV. As part of this study, doctors will take some of your own white blood cells, called T-cells, and modify them so that they can identify and target your HIV cells. The purpose of the …

antiretroviral therapy

hiv-1 rna measurement

hepatitis

hiv-1 infection

haart

27 views
27 Dec, 2020
1 location

Effects of Biktarvy on CFR in Stable HIV Patients

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single pill regimen that was approved by the FDA in February 2018 for treatment of HIV. The marketed name of the drug is Biktarvy. In two phase 3 comparative clinical trials, including one with ABC/3TC/DTG, it was found to be non-inferior to dolutegravir-containing regimens in …